Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
Abstract Aims The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease over a study period of 3 years. We aimed to inves...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2020-12-01
|
| Edice: | ESC Heart Failure |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/ehf2.12891 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|